CD24 Expressing Cells and Uses Thereof - Sana Biotechnology Patent EP4017508A1

The European Patent Office published Sana Biotechnology's patent application EP4017508A1 for CD24 expressing cells and uses thereof. The application covers immune-modulated cell compositions and methods for therapeutic use. This represents a significant IP positioning in the cell therapy space, particularly for treatments involving CD24-modified cells.

Competitors developing CD24-based or CD24-modified cell therapies for immune-related conditions should monitor this application. Researchers and companies in the cell therapy space may need to evaluate potential infringement risks or explore licensing arrangements with Sana Biotechnology upon patent grant.